Well the quality will vastly vary between Florence and Sicily in Italy. (just to give example)
No, the blog I read was about a patient living in a large Western capital city.
I often wonder if the healthcare is really that good in a crowded city. We know that rural areas do not have as good healthcare for many simple reasons. For example, how do we force specialists to relocate there against their will? But too big a city may not be good either because of crowding conditions.
And people often quote statistics relating healthcare costs to longevity. It shows US citizens have a shorter life than people in other developed countries, despite spending more. That is irrefutable. But what is the reason? Making observations is always a lot easier than understanding the causes.
I can think of many hypotheses, but will throw out a few I can think of on top of my head. Of course these are just hypotheses, but I hope researchers and policy makers would know about these kinds of things to prove or disprove them. One cannot fix something if he does not know how it broke.
Here are a couple of hypotheses. What if Americans are just, gasp, sicker than the world? So, it costs more for healthcare, but if we do not spend more than other nations, our longevity would be even shorter? If so, then we must take better care of ourselves, meaning getting better at prevention. How do Americans rate in terms of diabetes, high BP, obesity, etc...?
And then, I keep hearing about expensive treatments that only prolong a patient's life for a month or two. For example, doctors at Sloan-Kettering made the news when they refused to use certain cancer drugs that did not do much for the patients, other than ruined them financially.
So, look at the country as a whole. Suppose we spend $1M to treat 1 out of 100 patients and extend his life 1 year. We have boosted the average lifespan by 1/100th of a year. The payback is $100M per year of increased average lifespan.
Now, if we take that $1M and treat all 100 patients with $10K each. We could not help the unfortunate patient, but extend the life of the other 99 patients by 1 year. We have just boosted the average lifespan by 99/100th of a year. The payback is now $1M per average year of increased lifespan.
So, how do other countries handle experimental and expensive drugs and treatments? If they do not concentrate on the unfortunate patient, they will have better statistics to show.